Date published: 2025-12-22

1-800-457-3801

SCBT Portrait Logo
Seach Input

Vmn1r157 Inhibitors

The chemical class known as Vmn1r157 inhibitors is not defined by direct interaction with the Vmn1r157 receptor but through their ability to modulate various signaling pathways and cellular processes that are either upstream or downstream of the receptor's activity. These chemicals act on different molecular targets, each playing a role in the regulation of GPCR-mediated signaling. For instance, Propranolol and Losartan target other GPCRs and can thereby influence the overall signaling environment in which Vmn1r157 operates, potentially leading to a decrease in the functional activity of Vmn1r157 due to altered second messenger levels or receptor crosstalk. Risperidone, by modulating dopaminergic GPCR activity, can affect neurotransmitter balance and receptor desensitization patterns, possibly influencing responses that Vmn1r157 might mediate.

Inhibitors such as U0126, Wortmannin, Y-27632, and KN-62 target enzymes that are part of the signaling cascades initiated by GPCRs, thus potentially affecting Vmn1r157 signaling by changing the phosphorylation status of key signaling molecules or by altering the calcium dynamics that are crucial for GPCR function. Charybdotoxin and Aminoguanidine can alter the ionic environment or the levels of small signaling molecules like nitric oxide, respectively, which can have broad effects on GPCR-mediated cellular responses. Spironolactone, Dasatinib, and GF 109203X target hormone receptors and kinases, respectively, demonstrating how altering enzyme activity, gene expression, and other cellular processes can indirectly influence the function of GPCRs, including Vmn1r157.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Propranolol

525-66-6sc-507425
100 mg
$180.00
(0)

Blocks beta-adrenergic receptors, which can reduce sympathetic nervous system activity, potentially decreasing GPCR-mediated signaling that may intersect with Vmn1r157 pathways.

Losartan

114798-26-4sc-353662
100 mg
$127.00
18
(1)

Antagonizes angiotensin II receptors, thereby modulating GPCR-controlled blood pressure regulation systems that may indirectly affect Vmn1r157 signaling.

Risperidone

106266-06-2sc-204881
sc-204881A
sc-204881B
sc-204881C
10 mg
50 mg
1 g
5 g
$171.00
$705.00
$1000.00
$2000.00
1
(1)

Inhibits dopamine D2 receptors, thus dampening dopaminergic GPCR signaling that can intersect with the signaling mediated by Vmn1r157.

Charybdotoxin

95751-30-7sc-200979
100 µg
$401.00
9
(0)

Blocks specific potassium channels, which could shift the membrane potential and affect signaling cascades involving ion fluxes that GPCRs, including Vmn1r157, may regulate.

Spironolactone

52-01-7sc-204294
50 mg
$107.00
3
(1)

Blocks aldosterone receptors, which may adjust mineralocorticoid activity, impacting GPCR-related signaling that could be relevant to the regulation of Vmn1r157.

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$66.00
$219.00
$417.00
97
(3)

Inhibits PI3K, affecting phosphoinositide dynamics and potentially altering GPCR-mediated signaling pathways, including those associated with Vmn1r157.

Y-27632, free base

146986-50-7sc-3536
sc-3536A
5 mg
50 mg
$182.00
$693.00
88
(1)

Inhibits Rho-associated protein kinase, which can modulate the actin cytoskeleton and potentially affect GPCR-controlled cellular responses, including those involving Vmn1r157.

KN-62

127191-97-3sc-3560
1 mg
$133.00
20
(2)

Inhibits calcium/calmodulin-dependent protein kinase II, potentially affecting calcium signaling cascades that are regulated by GPCRs such as Vmn1r157.

Dasatinib

302962-49-8sc-358114
sc-358114A
25 mg
1 g
$47.00
$145.00
51
(1)

Inhibits Src family kinases, potentially altering kinase-mediated signaling pathways downstream of GPCR activation, which may include Vmn1r157.

Bisindolylmaleimide I (GF 109203X)

133052-90-1sc-24003A
sc-24003
1 mg
5 mg
$103.00
$237.00
36
(1)

Inhibits protein kinase C, which is involved in the signaling of many GPCRs and could modulate downstream signaling effects of Vmn1r157 activation.